Literature DB >> 10466818

Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization.

Andrea Speckner1, Diana Glykofrydes1, Mats Ohlin2, Michael Mach1.   

Abstract

Glycoprotein B (gB, gpUL55) is the major antigen for the induction of neutralizing antibodies against human cytomegalovirus (HCMV), making it an attractive molecule for active and passive immunoprophylaxis. The region between aa 552 and 635 of HCMV gB (termed AD-1) has been identified as the immunodominant target for the humoral immune response following natural infection. AD-1 represents a complex domain which requires a minimal continuous sequence of more than 70 aa for antibody binding. Neutralizing as well as non-neutralizing antibodies can bind to AD-1 in a competitive fashion. The fine specificity of AD-1-binding monoclonal antibodies (MAbs) and affinity-purified human polyclonal antibodies was analysed by using recombinant proteins containing single amino acid substitutions spanning the entire AD-1 domain. Our results revealed that all MAbs had individual patterns of binding to the mutant proteins indicating the presence of a considerable number of distinct antibody-binding sites on AD-1. The neutralization capacity of antibodies could not be predicted from their binding pattern to AD-1 mutant proteins. Polyclonal human antibodies purified from different convalescent sera showed identical binding patterns to the mutant proteins suggesting that the combined antibody specificities present in human sera are comparable between individuals. Neutralization capacities of polyclonal human AD-1 antibodies did not exceed 50% indicating that, during natural infection, a considerable proportion of non-neutralizing antibodies are induced and thus might provide an effective mechanism to evade complete virus neutralization.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10466818     DOI: 10.1099/0022-1317-80-8-2183

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  27 in total

1.  A trimeric capable gB CMV vaccine provides limited protection against a highly cell associated and epithelial tropic strain of cytomegalovirus in guinea pigs.

Authors:  K Yeon Choi; Nadia S El-Hamdi; Alistair McGregor
Journal:  J Gen Virol       Date:  2021-03-17       Impact factor: 3.891

2.  Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins.

Authors:  Elizabeth A Reap; Sergey A Dryga; John Morris; Bryan Rivers; Pamela K Norberg; Robert A Olmsted; Jeffrey D Chulay
Journal:  Clin Vaccine Immunol       Date:  2007-04-18

3.  Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus.

Authors:  Elizabeth A Reap; John Morris; Sergey A Dryga; Maureen Maughan; Todd Talarico; Robert E Esch; Sarah Negri; Bruce Burnett; Andrew Graham; Robert A Olmsted; Jeffrey D Chulay
Journal:  Vaccine       Date:  2007-08-30       Impact factor: 3.641

Review 4.  Role of antibodies in confining cytomegalovirus after reactivation from latency: three decades' résumé.

Authors:  Astrid Krmpotić; Jürgen Podlech; Matthias J Reddehase; William J Britt; Stipan Jonjić
Journal:  Med Microbiol Immunol       Date:  2019-03-28       Impact factor: 3.402

Review 5.  Virion Glycoprotein-Mediated Immune Evasion by Human Cytomegalovirus: a Sticky Virus Makes a Slick Getaway.

Authors:  Thomas J Gardner; Domenico Tortorella
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-15       Impact factor: 11.056

Review 6.  Cytomegalovirus Vaccines: Current Status and Future Prospects.

Authors:  K M Anderholm; C J Bierle; M R Schleiss
Journal:  Drugs       Date:  2016-11       Impact factor: 9.546

7.  Original Antigenic Sin Shapes the Immunological Repertoire Evoked by Human Cytomegalovirus Glycoprotein B/MF59 Vaccine in Seropositive Recipients.

Authors:  Ilona Baraniak; Florian Kern; Pavlo Holenya; Paul Griffiths; Matthew Reeves
Journal:  J Infect Dis       Date:  2019-06-19       Impact factor: 5.226

8.  Antigenic domain 1 is required for oligomerization of human cytomegalovirus glycoprotein B.

Authors:  William J Britt; Michael A Jarvis; Derek D Drummond; Michael Mach
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

9.  Glycoprotein B switches conformation during murid herpesvirus 4 entry.

Authors:  Laurent Gillet; Susanna Colaco; Philip G Stevenson
Journal:  J Gen Virol       Date:  2008-06       Impact factor: 3.891

10.  A Novel Non-Replication-Competent Cytomegalovirus Capsid Mutant Vaccine Strategy Is Effective in Reducing Congenital Infection.

Authors:  K Yeon Choi; Matthew Root; Alistair McGregor
Journal:  J Virol       Date:  2016-08-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.